Megestrolacetaat Teva

Megestrol acetate, the active ingredient in Megestrolacetaat Teva, is a progestogen presented as an oral dosage form for oral use. It is employed to treat cachexia associated with AIDS or cancer and to manage hormone‑responsive malignancies such as breast and endometrial cancer. GNH USA supplies Megestrolacetaat Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Megestrol acetate is a synthetic progestogen used in hormonal therapy for several serious conditions.

Cachexia (AIDS or cancer): improves appetite and promotes weight gain in patients with severe wasting. Breast cancer: provides antineoplastic activity in hormone‑responsive breast tumors. Endometrial cancer: used as hormonal therapy for advanced or recurrent disease.

Megestrol acetate may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Weight gain and fluid retention - Fatigue or lethargy

Serious or Rare Side Effects: - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Hepatic dysfunction or elevated liver enzymes - Severe hyperglycemia or new‑onset diabetes - Cushingoid syndrome (central obesity, moon face) - Anaphylactic or severe allergic reactions

When prescribing Megestrol acetate, clinicians should consider several safety measures.

Monitor blood glucose: patients with diabetes may require dose adjustments. Assess thromboembolic risk: avoid in individuals with a history of clotting disorders. Evaluate liver function: hepatic impairment can alter drug metabolism. Use caution in pregnancy: potential fetal risk; prescribe only when benefits outweigh risks. Store at room temperature: keep in the original packaging, protect from moisture and light.

Megestrol acetate can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): may increase clotting risk. - CYP3A4 inducers (e.g., rifampin): can reduce therapeutic effectiveness. - Antidiabetic agents: may exacerbate hypoglycemia or hyperglycemia.

Moderate Interactions (Monitor Closely): - Corticosteroids: additive glucocorticoid effects may worsen metabolic side effects. - Hormonal contraceptives: may diminish contraceptive efficacy. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise megesterol levels.